More activity has not made readiness easier to recognize
Healthcare marketers can see more buying activity than ever before. Website visits, content engagement, event participation, email responses, third-party intent, and seller activity all provide potential clues. Yet greater visibility has not necessarily made it easier to determine when an organization is actively evaluating a solution.
Healthcare buying decisions are shaped by large, fluid groups. A clinician may initiate the process, but information security, legal, finance, operations, and procurement can all influence whether the solution moves forward. Each stakeholder asks different questions and looks for different evidence, often before anyone contacts a vendor.
The challenge is not a lack of signals. It is determining which signals matter together, what they suggest about the decision, and when the pattern is strong enough to warrant action.
Why a single signal misleads
A visit to a website might show someone is interested, but it could just as well mean the person is a student, a current customer, or a competitor. A white paper download could reflect an active buying group or simply someone gathering background information. A sudden increase in research into a topic can still be misleading if the topic is broad or unrelated to the solution being sold.
Healthcare buying adds an extra layer of difficulty because interest and organizational readiness don’t always coincide. Although a clinical champion may see clear value in a product, IT may not have the capacity to implement it. A service line leader may want to move forward, while finance has not yet approved the business case. Moreover, procurement activity can indicate real progress, or it may simply be a routine sourcing exercise.
Treating any one action as a qualified opportunity creates false positives and can send sellers after accounts that are not ready. Buying momentum becomes more credible when multiple signals come from relevant members of the buying group and reflect a clear progression toward active evaluation.
What a buying pattern looks like
A meaningful pattern typically involves three kinds of evidence. The first is the behavior of the individuals involved: repeated research into a relevant problem, product category, or competitor. The second is the buying group’s behavior: engagement from different roles whose involvement fits the decision-making process. The third element is the business context: a reason the organization might act now, such as a new service line, a leadership change, a capital planning cycle, a regulatory requirement, or a technology modernization initiative.
Sequence matters as much as volume. Broad educational research followed by engagement with clinical evidence, integration requirements, pricing, and implementation information tells a different story than ten visits to the same introductory page. A sharp increase above an account’s usual activity level may also be more informative than steady, low-level engagement.
That progression will not always be linear. Stakeholders may enter the process at different times, research may happen concurrently, and activity may pause as budgets or organizational priorities change. The goal is not to force every account into a fixed sequence. It is to understand how the signals relate to one another and what they suggest about the buying decision.
Perfect data is not required. Teams do need enough visibility to identify relevant activity and a shared definition of what progress looks like for the healthcare decision they are trying to influence.
A med tech example
Imagine a medical technology company offering a connected monitoring system to healthcare systems. When a director of nursing goes to a page focused on reducing preventable deterioration and downloads a clinical outcomes summary, that is useful, but it doesn’t show active evaluation.
Over the next two weeks, first-party engagement shows that an informatics leader from the same health system has reviewed integration requirements and a finance stakeholder has attended a webinar on the cost of unplanned escalation. Third-party intent data shows increased account-level research into the company and its competitors. Additional visits to implementation content suggest the buying group may also be considering how to deploy the system across multiple facilities.
Together, these signals suggest that the account’s evaluation is becoming more active and that a broader buying group may be forming. The questions are expanding from the clinical problem to technical fit, economics, and implementation. Research into competing solutions suggests the account may be comparing options, while interest in deployment across multiple facilities points to a potentially broader opportunity. These signals do not confirm an imminent purchase, but they give the commercial team a stronger basis for deciding whether and how to engage.
The right approach is not to send the same product email to every contact. Marketing can provide the nursing leader with evidence tied to clinical workflow and outcomes. A subject matter expert can help the informatics stakeholder understand integration and governance. Sales can use the finance engagement to evaluate the business case and confirm whether funding has been secured. Account leadership should coordinate these actions so that the health system has a single, well-informed conversation rather than facing several separate ones.
Where Revenue Orchestration fits
Recognizing buying momentum is only useful if the organization can respond effectively. In our webinar, Demandbase introduced Signal, Score, Play, and Outcome as a practical framework for determining which signals matter, how strongly they indicate readiness, what action should follow, and whether that action advanced the opportunity.
Revenue Orchestration addresses the broader organizational challenge. At Marketbridge, we use Revenue Orchestration to help companies connect their GTM strategy to the operating model required to execute it. That includes aligning investment, roles, processes, data, technology, and measurement around the growth motions that matter most.
In the MedTech example, that framework would guide the response to the emerging opportunity. Revenue Orchestration would ensure Marketing, Sales, and subject matter experts agree on their roles, the necessary workflows and data connections are in place, and successful plays can be tested and expanded across other priority accounts.
The two work at different levels. Signal, Score, Play, and Outcome help a team act on buying momentum. Revenue Orchestration helps the organization turn that approach into a coordinated, repeatable way to drive growth.
Start with one decision you need to see earlier
Organizations don’t need to map every possible signal before they start. A better starting point is a key commercial movement where earlier recognition would affect the outcome. For example, this could be identifying health systems planning to replace the existing device, provider organizations assessing a new workflow platform, or employers beginning to reconsider a health benefit.
For that motion, answer five questions:
- What are the business or clinical situations that lead to demand?
- What beliefs are required of each of the roles involved?
- What signs are given by first-party, third-party, and seller signals to show there is movement?
- What combinations or sequences should cause a response?
- Who owns the next action, and what result will indicate that progress has been made?
This approach requires people to make sensible decisions. It distinguishes between interesting activities and evidence of readiness and, at the same time, highlights operational gaps, for example, a high-value signal having no owner or a key stakeholder having no relevant content. The team can then set up one signal-to-action loop, test it, and improve it before applying it to other journeys.
The advantage comes from seeing the decision form
Healthcare organizations usually don’t announce when a purchasing process has begun. Instead, the decision appears bit by bit through the questions people ask, the evidence they look for, and the colleagues who take part in the assessment. Marketing professionals and commercial managers who can identify these behaviors can detect building momentum earlier and support the buying group more effectively.
A signal can show you that an event has taken place, while a pattern can help you understand what might be happening, why it matters now, and what action the team should take next. This is the difference between simply tracking activity and supporting a complex healthcare decision.
Schedule a strategy session with Marketbridge and Demandbase and discover which buying signals you need to be seeing earlier.
